1. Home
  2. VRCA vs EVG Comparison

VRCA vs EVG Comparison

Compare VRCA & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$6.15

Market Cap

137.3M

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

EVG

Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

HOLD

Current Price

$10.68

Market Cap

142.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRCA
EVG
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
137.3M
142.9M
IPO Year
2018
2004

Fundamental Metrics

Financial Performance
Metric
VRCA
EVG
Price
$6.15
$10.68
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$17.00
N/A
AVG Volume (30 Days)
83.8K
40.7K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$94.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
370.22
N/A
52 Week Low
$0.49
$10.40
52 Week High
$9.82
$11.45

Technical Indicators

Market Signals
Indicator
VRCA
EVG
Relative Strength Index (RSI) 45.71 46.03
Support Level $5.13 $10.65
Resistance Level $6.40 $11.07
Average True Range (ATR) 0.73 0.13
MACD -0.20 -0.02
Stochastic Oscillator 21.52 25.00

Price Performance

Historical Comparison
VRCA
EVG

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

Share on Social Networks: